Abstract

Tumors of the central nervous system (CNS) account for about 2% of all the cancers, and gliomas are the most common tumors of CNS. Although there is a great improvement of the diagnosis and treatment, the prognosis of glioma is poor and this tumor remains incurable. We conducted a perspective case cohort study to examine the role of genetic polymorphisms in Excision repair cross-complementing group 1 (ERCC1) and xeroderma pigmentosum group D (XPD) on the prognosis of glioma in Chinese population. Three hundred and fifty patients that underwent procarbazine, lomustine, and vincristine (PCV) chemotherapy were selected between November 2007 and November 2011, and all of them were followed-up till April 2012. The genotyping of ERCC1 118C/T (rs3212986), ERCC1 8092C/A(rs11615), XPD Lys751Gln(rs13181) and XPD Asp312Asn(rs1799793) was performed by TaqMan assays. The Cox’s regression analysis showed individuals carrying ERCC1 118 T/T genotype with 0.56 fold risk of death from glioma than ERCC1 118 T/T genotype (HR=0.56, 95%CI=0.33-0.87). Meanwhile, XPD 751Gln/Gln had a moderate lower hazard ratio (HR) of glioma in comparison to XPD Lys/Lys carriers (HR=0.53, 95%CI=0.37-0.94). In conclusion, our present data indicated that polymorphisms in ERCC1 118C/T (rs3212986) and XPD Lys751Gln(rs13181) have a role in the prognosis of glioma.

Key words: DNA repaired gene, glioma, chemotherapy, prognosis.